Axonics, Inc. (NASDAQ:AXNX) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET

Company Participants

Neil Bhalodkar - Vice President of Investor Relations

Raymond Cohen - Chief Executive Officer

Dan Dearen - President & Chief Financial Officer

Conference Call Participants

Adam Maeder - Piper Sandler

Chris Pasquale - Nephron Research

Travis Steed - Bank of America Securities

David Rescott - Truist

Cecilia Furlong - Morgan Stanley

Michael Polark - Wolfe Research

Mike Matson - Needham & Company

Operator

Good day and thank you for standing by. Welcome to Axonics Q3 2022 Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand the conference over to your speaker today, Neil Bhalodkar. Please go ahead.

Neil Bhalodkar

Thank you. Good afternoon and thank you for joining Axonics' third quarter 2022 results and update call. Presenting on today's call are Raymond Cohen, Chief Executive Officer; and Dan Dearen, President and Chief Financial Officer.

Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in Axonics' filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Listeners are cautioned not to place undue reliance on these forward-looking statements which speak only as of today's date, October 31, 2022. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances or unanticipated events that may arise.

With that, I'd like to now turn the call over to Ray.

Raymond Cohen

Thanks, Neil. I'd like to welcome everyone joining this call this afternoon. And before I begin with my remarks, I want to note 2 really notable events that is today on October 31, Halloween, is exactly 4 years since the date of our initial public offering. So it's kind of a big day for us today with our 4-year anniversary. And moreover, on November 1 which would be tomorrow, was the date of our first U.S. implant of a sacral neuromodulation device in America. So October 31, November 1, these are dates that they really resonate with us at Axonics.